9VA-23193-83036
2 vaccinations
4 coded responses
24 check-ins
4 free-text entries
0 call cases
- Sex
- Male
- Age at first dose
- 0-4
- ZIP prefix
- 875 / NM
- Registered
- 2022-06-25
- Relationship
- Child or adolescent in my care
- Guardian
- 5MA-63554-05753
- Race
- White
- Ethnicity
- N/A
Timeline
-
2022-06-25
Registered in v-safe
-
2022-06-25
Dose 1 — Moderna
- 2022-06-25
-
2022-06-26
Health check-in — days 1–6 daily, dose 1, dependentFeeling: Good · Site: Pain · NoneAdult check-in
-
2022-06-27
Survey response — days 1–6 daily, dose 1, dependentMedDRA: Injection site bruising — Feeling: Good · Site: PainFree text: Bruising at inj siteMedDRA releases: 2024-11 · check-in free text available
-
2022-06-28
Survey response — days 1–6 daily, dose 1, dependentMedDRA: Injection site bruising — Feeling: Good · DiarrheaFree text: Bruise at inj siteMedDRA releases: 2024-11 · check-in free text available
- 2022-06-29
- 2022-06-30
- 2022-07-01
- 2022-07-02
-
2022-07-09
Survey response — day 14, dose 1, dependentMedDRA: Rash, Rash macular, Urticaria — Feeling: GoodFree text: Targetoid macular rash on bilateral soles of feet, bilateral legs, bilateral thighs, bilateral palms of hands lasting 5 days. Day 3 of that, urticaria-like rash on left ankle.MedDRA releases: 2024-11 · check-in free text available
- 2022-07-16
-
2022-07-23
Dose 2 — Moderna
-
2022-07-23
Health check-in — day 0, dose 2, dependentFeeling: Good · Site: Pain, Redness, Swelling · NoneAdult check-in
-
2022-07-24
Health check-in — days 1–6 daily, dose 2, dependentFeeling: Good · Site: Pain, Swelling · Fatigue or tirednessAdult check-in
-
2022-07-25
Health check-in — days 1–6 daily, dose 2, dependentFeeling: Good · Site: Pain, Redness, Swelling · NoneAdult check-in
- 2022-07-26
- 2022-07-27
- 2022-07-28
- 2022-07-30
-
2022-08-07
Survey response — day 14, dose 2, dependentMedDRA: Rash, Rash erythematous, Rash macular, Reaction to previous exposure to any vaccine — Feeling: GoodFree text: Rash on bilateral soles of feet: mostly circular, macular, clear in middle, pink around the outside. Area of rash on palmar side of left thumb- red, macular, asymmetrical. This rash appeared 8/7. Similar to rash noted after the first dose. No fever.MedDRA releases: 2024-11 · check-in free text available
- 2022-08-14
- 2022-08-20
- 2022-08-27
- 2022-09-05
- 2022-10-22
- 2023-01-21
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2022-06-25 | Moderna | No |
| 2 | 2022-07-23 | Moderna | No |
Free text
Release 12 — days 1–6 daily, dose 1, dependent
Systemic reaction (other): Bruising at inj site
Systemic reaction (other): Bruise at inj site
Release 12 — day 14, dose 1, dependent
Symptoms: Targetoid macular rash on bilateral soles of feet, bilateral legs, bilateral thighs, bilateral palms of hands lasting 5 days. Day 3 of that, urticaria-like rash on left ankle.
Release 12 — day 14, dose 2, dependent
Symptoms: Rash on bilateral soles of feet: mostly circular, macular, clear in middle, pink around the outside. Area of rash on palmar side of left thumb- red, macular, asymmetrical. This rash appeared 8/7. Similar to rash noted after the first dose. No fever. cut off by CDC
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Rash | · | · | ✓ |
| SD | Rash erythematous | · | · | ✓ |
| SD | Rash macular | · | · | ✓ |
| SD | Reaction to previous exposure to any vaccine | · | · | ✓ |
| SD | Urticaria | · | · | ✓ |
| SRO | Injection site bruising | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release